Eris Lifesciences Ltd
NSE:ERIS
Net Margin
Eris Lifesciences Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Eris Lifesciences Ltd
NSE:ERIS
|
191.8B INR |
12%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
779.4B USD |
24%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
394B USD |
16%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
2.1T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
233.4B CHF |
20%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
174.8B GBP |
13%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
198.5B CHF |
23%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
225.9B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
167.6B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
142.8B USD |
13%
|
Eris Lifesciences Ltd
Glance View
Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue. The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Eris Lifesciences Ltd's most recent financial statements, the company has Net Margin of 12%.
You don't have any saved screeners yet